Destiny Pharma Share Discussion Threads

[brooko19] 01/2/2024 09:42

I have emailed him John to suggest he does not sure if the email I have is correct if I don’t get a reply I’ll email through the website

[john henry] 01/2/2024 09:41

Brooko19 ive never seen a Tovey doing a one on one interview, therefore i suspect you wont see one.
Looking at the collapse in the share price imho he should.

[brooko19] 01/2/2024 09:39

Another clown more like

[s34icknote] 01/2/2024 09:29

Another cash raise by middle of year to keep the wages paid !

[brooko19] 01/2/2024 08:49

It would help if they do a proactive interview to clear any concerns people have, IMO I think people worrying about nothing but I get a big drop causes fear

[john henry] 01/2/2024 08:40

Theres going to be churn around these levels for a few days.

[brooko19] 01/2/2024 08:36

I think JH right, seller don’t care now mms are getting rid of it hoping this means they are nearly out.

[marvelman] 01/2/2024 08:29

They are playing the chart game

[john henry] 01/2/2024 08:25

PA checking out the lows of yesterday.

MMs clearing a sell order imho

[jeanesy] 01/2/2024 08:17

looks like investors are deserting a sinking ship here !

[marvelman] 31/1/2024 17:58

I agree Arab :-))

[arab3] 31/1/2024 17:30

madness indeed
i think the saner heads were the ones selling at all the spikes !

[banshee] 31/1/2024 16:59

Let's hope there are no further similar issues to be unveiled, that would not go down well. They have been working with XF much longer than M3 and it's a very different beast, but a culture of non-professionalism (even if it is now historic), at a small bio will still make potential partners wary.

[controlledmadness] 31/1/2024 16:37

Looks like there is some panic selling. I assume its from those who do not understand pharmacutical companies.
But the buys are greater then the sells so it looks like saner heads think this is a good price to buy.

[henley2] 31/1/2024 16:26

Yes I know that, I can read too. But it’s obvious that the market would like some clarification from the company itself and some reassurance about XF73 nasal progress.

[brooko19] 31/1/2024 16:18

It clearly states in RNS any trials will be at the expense on Sebela

[waterloo01] 31/1/2024 16:18

Some people don't seem to read

[henley2] 31/1/2024 16:16

Well he could set out how long the delay is likely to be before P3 can start and how much if any it will cost Destiny.

[marvelman] 31/1/2024 16:09

I don't think there is anything else to explain now Henley..apart from XF73 nasal which is of course is the only one that really matters for now

[arab3] 31/1/2024 15:28

279p is he on drugs !

[marvelman] 31/1/2024 15:23

...but alas we won't be getting stage payments anytime soon it would seem

[edmonda] 31/1/2024 15:22

Clinical Development Updates - new research note with audio summary from Equity Development here:

Destiny Pharma has started the year with two important clinical development updates on its lead products which enhance both their profiles.

The clinical development update on XF-73 Dermal, which is a variation on Destiny’s XF-73 Nasal product included a preclinical study of an XF-73 Dermal formulation demonstrating that like XF-73 Nasal, it is also safe and applications to wounds results in negligible systemic levels.

On the non-toxigenic Clostridioides difficile strain M3, Destiny and partner Sebela Pharmaceuticals improved M3’s chemistry, manufacturing and controls program to incorporate a solid dose, rather than liquid formulation – which should improve patient compliance, manufacturing and storage costs – and changed the product’s contract manufacturer. While these changes may necessitate a bridging study between the two dosage forms, the costs all future M3 studies will be met by Destiny’s partner.

Our fair value remains unchanged at £245.7m, or 279 pence per share.

[barony] 31/1/2024 15:19

Can’t see anything -ve in this rns. In fact, it looks like the dermal product may be put to market earlier than anticipated. We wait for the nasal product, but any additional test costs are not down to us.